Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 9/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815323 | 0.82 | HCRTR2 (0.43) | HCRTR1HCRTR2HSD11B1SYKTAS2R14 | |
| SCHEMBL14815483 | 0.82 | HTR1A (0.42) | HCRTR1HCRTR2HDAC8SYKSLC6A7 | |
| SCHEMBL14814765 | 0.78 | HCRTR1 (0.41) | HCRTR1HCRTR2SYKPKM | |
| SCHEMBL14815286 | 0.77 | SYK (0.42) | HSD11B1HDAC8SYK | |
| SCHEMBL14815306 | 0.77 | EPHX2 (0.43) | HCRTR1HCRTR2HSD11B1 | |
| SCHEMBL14815488 | 0.75 | SYK (0.35) | HCRTR1HCRTR2SYK | |
| SCHEMBL14833380 | 0.72 | HSD11B1 (0.45) | HCRTR1HCRTR2HSD11B1HDAC8SYK | |
| SCHEMBL14814985 | 0.72 | HSD11B1 (0.45) | HCRTR1HCRTR2HSD11B1HDAC8SYK | |
| SCHEMBL14815100 | 0.71 | HCRTR2 (0.41) | HCRTR1HCRTR2HSD11B1TAS2R14 | |
| SCHEMBL14814728 | 0.69 | HCRTR2 (0.39) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | HCRTR1 654/4885HCRTR2 434/4885HSD11B1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.